Board Committees

The Board meets at least four times per year for formal meetings. It approves financial statements, dividends and significant changes in accounting practices and key commercial matters, such as decisions to be taken on whether to take forward or to cancel a material collaboration project or commercial agreement.

The Board has established three subcommittees with formally delegated duties and responsibilities, as summarized below:

Chair

Member

Chairman of the board

Financial expert

The Audit Committee’s principal functions include ensuring that appropriate systems of accounting and financial controls are in place, monitoring the integrity of the Group’s financial statements, reviewing the effectiveness of the accounting and internal control systems, reviewing reports from the Group’s auditors relating to accounting and internal controls, and reviewing the interim and annual results and reports to shareholders, in all cases having due regard to the interests of shareholders.

Audit Committee	Position
Dr. David Holbrook MA, MB BS, MBA Dr. David Holbrook is a proven leader in business development and healthcare investing, with over 30 years’ experience in the life sciences sector. David, a qualified physician and MBA graduate from Harvard Business School, has worked for a variety of companies, charities and academic institutions including: GlaxoSmithKline, Roche, Imperial College London and the University of Cambridge. In addition to his non-executive directorship at OBD, David will continue in his roles as Head of Seed Funds at LifeArc, Senior Independent Director at Worldwide Healthcare Trust plc and Chairman of The Liver Group Charity. David brings a wealth of healthcare investment expertise as a former General Partner and Head of Healthcare Investing at MTI Ventures LLP, and Director, Life Sciences at the Cambridge University Seed Fund.	Chair
Matthew Wakefield LLB, MBA Matthew has spent 27 years in the City working in senior positions in both fund management and investment banking. He started his career as a fund manager at Legal and General Plc before moving into broking at Nomura Holdings, Inc. He joined Collins Stewart Hawkpoint Limited in 1992 and was Head of Sales and a member of the management committee. After 12 years, he left to work for two charities, The Besom Foundation and The 999 Club. In 2011, Matthew set up the broking partnership Baden Hill LLP, where he remains as a partner and shareholder. He has a degree in law and an MBA in finance.	Member
Audit Committee Terms of Reference	Download

The Remuneration Committee is responsible for determining and agreeing with the Board the framework for the remuneration packages for each of the Executive Directors (the remuneration of the Non-Executive Directors is determined by the Board). The Remuneration Committee considers all aspects of the Executive Directors’ remuneration, including pensions, bonus arrangements, benefits, incentive payments and share option awards, and the policy for, and scope of, any termination payments. No Director is involved in discussions relating to their own remuneration.

Remuneration Committee	Position
Dr. David Holbrook MA, MB BS, MBA Dr. David Holbrook is a proven leader in business development and healthcare investing, with over 30 years’ experience in the life sciences sector. David, a qualified physician and MBA graduate from Harvard Business School, has worked for a variety of companies, charities and academic institutions including: GlaxoSmithKline, Roche, Imperial College London and the University of Cambridge. In addition to his non-executive directorship at OBD, David will continue in his roles as Head of Seed Funds at LifeArc, Senior Independent Director at Worldwide Healthcare Trust plc and Chairman of The Liver Group Charity. David brings a wealth of healthcare investment expertise as a former General Partner and Head of Healthcare Investing at MTI Ventures LLP, and Director, Life Sciences at the Cambridge University Seed Fund.	Chair
Matthew Wakefield LLB, MBA Matthew has spent 27 years in the City working in senior positions in both fund management and investment banking. He started his career as a fund manager at Legal and General Plc before moving into broking at Nomura Holdings, Inc. He joined Collins Stewart Hawkpoint Limited in 1992 and was Head of Sales and a member of the management committee. After 12 years, he left to work for two charities, The Besom Foundation and The 999 Club. In 2011, Matthew set up the broking partnership Baden Hill LLP, where he remains as a partner and shareholder. He has a degree in law and an MBA in finance.	Member
Remuneration Committee Terms of Reference	Download

The Nomination Committee is responsible for reviewing the structure, size and composition of the Board based upon the skills, knowledge and experience required to ensure that it continues to operate effectively. The Nomination Committee also identifies and nominates suitable candidates to join the Board when vacancies arise and makes recommendations to the Board for the reappointment of any Non-Executive Directors.

Nomination Committee	Position
Matthew Wakefield LLB, MBA Matthew has spent 27 years in the City working in senior positions in both fund management and investment banking. He started his career as a fund manager at Legal and General Plc before moving into broking at Nomura Holdings, Inc. He joined Collins Stewart Hawkpoint Limited in 1992 and was Head of Sales and a member of the management committee. After 12 years, he left to work for two charities, The Besom Foundation and The 999 Club. In 2011, Matthew set up the broking partnership Baden Hill LLP, where he remains as a partner and shareholder. He has a degree in law and an MBA in finance.	Chair
Jon Burrows BSc, MSc, PhD Jon’s 25yr career in science and medicine has been built on increasing levels of responsibility in scientific leadership, business development, commercialization and executive management at both early-stage biotech and large multinational biomedical entities including Pharmacia/SUGEN, Rigel, Chiron, Novartis, Ventana, Roche, Expression Pathology and OncoPlex Diagnostics. In his early career, Jon was in oncology drug development, where he became skilled at driving molecular diagnostics tied to drug development to advance precision medicine and advocate for personalized healthcare. Most recently Jon was a Managing Partner at Oncology Partners (NYC), a consulting and clinical advisory firm he co-founded, focused on providing strategic counsel to development stage pharma, biotech, medical devices and diagnostic companies. Previously Jon was president and CEO of OncoPlex Diagnostics, a pioneer in clinical proteomics for oncology. Under his leadership OncoPlex was transformed from a private, pre-revenue stage company into a thriving clinical diagnostics business with marketed products, which was ultimately acquired by NantOmics in May 2015. Jon received his BSc (Hons) degree in Industrial Chemistry (color) from Leeds University in England. He subsequently completed an MSc in Physical Chemistry and a Ph.D in Cell & Molecular Biology at the University of Nevada, Reno. Before going into the Pharma Industry, he was a Postdoc and then the Alpha One Foundation Fellow in the lab of Dr David Perlmutter at the Children’s hospital at Washington University in St Louis.	Member
Dr. David Holbrook MA, MB BS, MBA Dr. David Holbrook is a proven leader in business development and healthcare investing, with over 30 years’ experience in the life sciences sector. David, a qualified physician and MBA graduate from Harvard Business School, has worked for a variety of companies, charities and academic institutions including: GlaxoSmithKline, Roche, Imperial College London and the University of Cambridge. In addition to his non-executive directorship at OBD, David will continue in his roles as Head of Seed Funds at LifeArc, Senior Independent Director at Worldwide Healthcare Trust plc and Chairman of The Liver Group Charity. David brings a wealth of healthcare investment expertise as a former General Partner and Head of Healthcare Investing at MTI Ventures LLP, and Director, Life Sciences at the Cambridge University Seed Fund.	Member
Nomination Committee Terms of Reference	Download

Dr. David Holbrook MA, MB BS, MBA

Dr. David Holbrook is a proven leader in business development and healthcare investing, with over 30 years’ experience in the life sciences sector. David, a qualified physician and MBA graduate from Harvard Business School, has worked for a variety of companies, charities and academic institutions including: GlaxoSmithKline, Roche, Imperial College London and the University of Cambridge. In addition to his non-executive directorship at OBD, David will continue in his roles as Head of Seed Funds at LifeArc, Senior Independent Director at Worldwide Healthcare Trust plc and Chairman of The Liver Group Charity. David brings a wealth of healthcare investment expertise as a former General Partner and Head of Healthcare Investing at MTI Ventures LLP, and Director, Life Sciences at the Cambridge University Seed Fund.

Matthew Wakefield LLB, MBA

Matthew has spent 27 years in the City working in senior positions in both fund management and investment banking. He started his career as a fund manager at Legal and General Plc before moving into broking at Nomura Holdings, Inc. He joined Collins Stewart Hawkpoint Limited in 1992 and was Head of Sales and a member of the management committee. After 12 years, he left to work for two charities, The Besom Foundation and The 999 Club. In 2011, Matthew set up the broking partnership Baden Hill LLP, where he remains as a partner and shareholder. He has a degree in law and an MBA in finance.

Dr. David Holbrook MA, MB BS, MBA

Matthew Wakefield LLB, MBA

Jon Burrows BSc, MSc, PhD

Jon’s 25yr career in science and medicine has been built on increasing levels of responsibility in scientific leadership, business development, commercialization and executive management at both early-stage biotech and large multinational biomedical entities including Pharmacia/SUGEN, Rigel, Chiron, Novartis, Ventana, Roche, Expression Pathology and OncoPlex Diagnostics.

In his early career, Jon was in oncology drug development, where he became skilled at driving molecular diagnostics tied to drug development to advance precision medicine and advocate for personalized healthcare.

Most recently Jon was a Managing Partner at Oncology Partners (NYC), a consulting and clinical advisory firm he co-founded, focused on providing strategic counsel to development stage pharma, biotech, medical devices and diagnostic companies.

Previously Jon was president and CEO of OncoPlex Diagnostics, a pioneer in clinical proteomics for oncology. Under his leadership OncoPlex was transformed from a private, pre-revenue stage company into a thriving clinical diagnostics business with marketed products, which was ultimately acquired by NantOmics in May 2015.

Jon received his BSc (Hons) degree in Industrial Chemistry (color) from Leeds University in England. He subsequently completed an MSc in Physical Chemistry and a Ph.D in Cell & Molecular Biology at the University of Nevada, Reno. Before going into the Pharma Industry, he was a Postdoc and then the Alpha One Foundation Fellow in the lab of Dr David Perlmutter at the Children’s hospital at Washington University in St Louis.